{
    "symbol": "EXAS",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-26 21:34:13",
    "content": " Highlights from the first quarter include, testing more than a million people globally, growing revenue 24% excluding our COVID testing, partnering with Katie Couric on an exciting new campaign to get more people screened with Cologuard, optimizing our Sales force structure to reach primary care doctors more effectively and more efficiently, guiding a record number of patients to more effective cancer treatments with Oncotype DX, generating evidence to support our next generation Cologuard and multi-cancer early detection tests, focusing intently on prioritization and growing our company efficiently and beginning to integrate PreventionGenetics into our foundation. In colorectal cancer screening, we've made great progress enrolling cases to power our prospective BLUE-C study, and we remain on track to complete stool enrollment midyear, we expect BLUE-C results to support FDA submissions for our next generation Cologuard and colon blood tests. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. I know on the last call, you had mentioned you're baking about $220 million in rescreening revenues within this year's full year guide and about $100 million for Cologuard $45 million. Your line is open. Again, if we had a 100% sensitive blood-based test that was 100% specific under the USPSTF modeling approach -- it has a very difficult time with -- or it's on the border line for making a one-year interval. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}